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Abstract
Incremental doses of intravenous labetalol are safe and effective and, at times, such therapy may
need to be augmented by a continuous infusion of labetalol to control severe hypertension.
Continuous infusions of labetalol may exceed the recommended maximum daily dose of 300 mg
on occasion. We report a case in which hypertension occurring after an abdominal aortic aneurysm
repair, initially responsive to intermittent intravenous beta-blockade, became resistant to this
therapy leading to the choice of an intravenous labetalol infusion as the therapeutic option. The
labetalol infusion resulted in a profound cardiovascular compromise in this postoperative critically
ill patient. While infusions of labetalol have successfully been used, prolonged administration in the
intensive care unit requires vigilance and the establishment of a therapeutic rationale/policy for
interventions, such as the ready availability of glucagon, β-agonists, phosphodiesterase inhibitors,
insulin, and vasopressin when severe cardiovascular depression occurs.
Background
Labetalol is a non-selective β-adrenergic receptor antago-
nist, and a post-synaptic α-adrenergic receptor antagonist.
It is used in the treatment of essential hypertension, renal
hypertension, hypertension of pregnancy, pheochromo-
cytoma, and hypertensive crises. It can be administered
orally or intravenously. The β/α ratio of antagonism is 7:1
after intravenous administration (a 3:1 ratio exists after
oral administration). The drug is lipid-soluble, has a 25%
bioavailability, is devoid of active metabolites, and has a
half-life of approximately 5.5 hours. Labetalol decreases
blood pressure with a limited effect on cardiac output and
heart rate at recommended dosages. Its side effects include
postural hypotension/dizziness, fatigue, headache,
rashes, impotence, urinary retention, gastrointestinal
problems, asthma, Raynaud's phenomenon, and heart
failure [1].
Incremental doses of intravenous labetalol have been
demonstrated to be safe and effective [2,3]. A continuous
infusion of up to 2 mg/min, or intermittent intravenous
(IV) injections of 40 mg or 80 mg following an initial
injection have been recommended, to a maximum of 300
mg [2-4]. Long term continuous infusions of labetalol
that have exceeded the 300 mg maximum recommenda-
tion by the manufacturer have successfully been used to
control severe hypertension in medical and trauma
patients [5,6]. However, profound hypotension has also
been associated with an infusion dose that nears or
exceeds the maximum recommended [7].
We report a case of labetalol infusion overdose in which
profound hypotension and bradycardia occurred in a
hypertensive patient after abdominal aortic aneurysm
repair. The patient received an infusion that exceeded the
Published: 27 May 2008
Patient Safety in Surgery 2008, 2:13 doi:10.1186/1754-9493-2-13
Received: 18 April 2008
Accepted: 27 May 2008
This article is available from: http://www.pssjournal.com/content/2/1/13
© 2008 Fahed et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Patient Safety in Surgery 2008, 2:13 http://www.pssjournal.com/content/2/1/13
Page 2 of 4
(page number not for citation purposes)
manufacturer's recommended cumulative dosage and was
rescued with IV glucagon.
Case presentation
A 75 year old 61 kg white female was admitted to the sur-
gical intensive care (SICU) unit after an elective abdomi-
nal aortic aneurysm repair. Past medical history included
hypertension, renal cell carcinoma, left breast cancer, and
peripheral vascular disease. Past surgical history included
tonsillectomy, hysterectomy, cholecystectomy, left
nephrectomy, left adrenalectomy, and left breast lumpec-
tomy. Her home medications included nitroglycerin, ver-
apamil, and furosemide. She claimed allergies to sulfa,
ciprofloxacin, fexofenadine, codeine, cortisone, pheny-
toin, fluconazole, metoclopramide, penicillin, cisapride,
erythromycin, and sertraline.
Intraoperatively her blood pressure was controlled with
intravenous nitroglycerin, sodium nitroprusside, and
metoprolol, and she arrived in the SICU hemodynami-
cally stable. Her SICU stay was prolonged by a ventilator
associated pneumonia and renal insufficiency. For the
first twelve postoperative days her hypertension was con-
trolled with intermittent labetalol and a nitroglycerin
infusion. On postoperative days 13 through 20 her hyper-
tension required only intermittent IV metoprolol. On
postoperative day 21 she developed hypertension that did
not respond to intermittent beta blockade (systolic blood
pressures of 160–202 mm Hg) and the decision was made
to start the patient on a labetalol infusion at 0.5 mg/min.
The infusion varied between 0.5 mg/min and 2.0 mg/min.
After 16 hours of the infusion her blood pressure dropped
to 60/40 mm Hg with a heart rate of 58 beats per minute
and a central venous pressure (CVP) of 5 cm H2O. The
patient had received 1637 mg of labetalol over 16 hours
(102.3 mg/hr, see figure 1). Beta-blocker overdose was
suspected and glucagon was ordered, but it was not imme-
diately available. The patient was given one liter of 0.9%
NaCl rapidly, ephedrine 5 mg IV twice, and atropine 0.5
mg IV without result. A dopamine infusion of 10 mcg/
min was also ineffective. Two doses of 10 mcg of epine-
phrine IV raised the systolic blood pressure to 70 mm Hg
and the heart rate to 65 beats per minute. An epinephrine
infusion was then started at 0.05 mcg/kg/min. The gluca-
gon arrived 10 minutes after being ordered and 3.5 mg IV
(.05 mg/kg) was given over 3 minutes. The patient's blood
pressure promptly recovered to 94/47 mm Hg, heart rate
to 73/min, and a CVP of 14 cm H2O. The glucagon bolus
was followed by an infusion of glucagon 1 mg/hr for 27.5
hours (approximately 5 half-lives). After the glucagon
The vital signs and the cumulative labetalol dose over time Figure 1
The vital signs and the cumulative labetalol dose over time. MAP = mean arterial pressure; mg = milligrams; and mm Hg = mil-
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bolus the patient's blood sugar transiently reached 255
mg/dl. This was corrected with one dose of intravenous
insulin and, thereafter, the glucose remained less than 150
mg/dl. The epinephrine infusion was gradually discontin-
ued over 3 hours.
During the acute event the patient's breathing was con-
trolled in a synchronized intermittent mandatory ventila-
tion mode. The FiO2 was increased from 40% to 100%
FiO2 with a resultant ABG of pH 7.45, PaCO2 36 mm Hg,
PaO2 312 mm Hg, and HCO3 25 meq/L. The patient's
cardiac enzymes were normal and the transthoracic
echocardiogram demonstrated normal systolic and
diastolic function in the face of left ventricular hypertro-
phy and moderate mitral regurgitation (which were pre-
existing). The electrocardiogram was normal and the chest
roentgenogram showed no changes from the morning
film.
On post-operative day 24 she received a tracheostomy and
on hospital day 45 (post-operative day 44) she was dis-
charged to a long-term facility where she expired 6
months later.
Discussion
Labetalol infusion rates of 0.5–2 mg/minute have been
used without incident to achieve blood pressure control
[7-10], including long-term continuous infusions of 20–
30 mg/hour IV for 5 days [4] and 120–180 mg/hour for 14
days [5] without incident. However, severe refractory
hypotension with labetalol may occur, leading to death or
severe cardiac dysfunction [11,12]. The maximum cumu-
lative dose of labetalol used in U.S. clinical trials was 300
mg IV [2-4]. This dosing recommendation may easily be
exceeded with a five-hour infusion. The blocking of β-
receptors prevents the conversion of adenosine triphos-
phate to cyclic adenosine monophosphate by the respon-
sible G protein, thereby reducing the amount of cytosolic
calcium available for muscular contraction [13]. Besides a
reduction in cytosolic calcium, fluctuations in glucose lev-
els are possible with β-blocker overdose, but are rare
[14,15]. Glucagon is normally secreted by the pancreas in
response to hypoglycemia, causing the liver to convert
stored glycogen into glucose. Glucagon-treated patients
may present with the side effects of nausea, vomiting,
hypokalemia, and hyperglycemia [16]. As indicated
above, our patient had a transient hyperglycemia with the
glucagon bolus, but she did not demonstrate nausea,
vomiting, or hypokalemia.
For profound β-blocker blockade 0.05–.15 mg/kg of glu-
cagon is administered IV and then followed by 1–5 mg/hr
continuous infusion until symptoms subside (this may
take as much as 5 labetalol half-lives) [8]. Severe hypoten-
sion may occur at the time of administration [11,17], or
several hours after discontinuation [18,19]. A labetalol
infusion leading to β-blocker toxicity has been previously
reported once. It occurred in a patient with a subarach-
noid hemorrhage and multiple cerebral aneurysms who
required hypertension control [6]. The fact that labetalol-
induced hypotension may be refractory and can lead to
cardiovascular compromise and death is an issue of
patient safety [11,12].
Glucagon has been previously used as a rescue measure in
β-blocker overdose [20,21], as occurred in this case, but
evidence of the use of glucagon as the sole rescue drug is
limited [21,22]. In this report, the successful use of gluca-
gon was supported by the use of other drugs. In addition
to glucagon, intravenous epinephrine [13], phosphodi-
esterase inhibitors [18,21,23], insulin [24], and vaso-
pressin [6,25] have also been effective. The mechanisms
of action for these drugs are as follow: (1) epinephrine
binds to β-receptors that are not bound by the β-blocker,
thus activating adenyl cyclase through the Gs protein,
resulting in the release of calcium via the adenosine tri-
phosphate – adenosine monophosphate (AMP) – protein
kinase A pathway [13]; (2) glucagon acts directly on the Gs
protein foregoing the β-receptors entirely [13]; (3) phos-
phodiesterase inhibitors prevent the degradation of cyclic
AMP [13]; (4) insulin allows the uptake of carbohydrates
(energy), it is anti-inflammatory, and is associated with
potassium influx that results in prolonged repolarization
allowing calcium channels to remain open for a longer
time [13]; and (5) vasopressin works through the V1A
receptor where its activity is mediated by G proteins which
stimulate a phosphatidylinositol-calcium secondary mes-
senger system [26]. Furthermore, Jiraj et al have hypothe-
sized that some patients may have significant
pharmacologic/physiologic sensitivities to the α1 block-
ing and/or β2 agonist properties of labetalol, therefore
vasopressin may be effective through the V1 receptor
[6,25]. Profound hypotension in the face of vasopressors
may indicate a disabled vascular response, or vasoplegia,
which may be due to genetic variability [27].
At our institution vasopressin, phosphodiesterase inhibi-
tors, insulin and vasopressin are more readily available
than glucagon. However, except for the use of epine-
phrine, we did not consider these medications during this
clinical event. Additionally, interventions other than a
labetalol drip could have been entertained for the control
of blood pressure. According to the Vascular Biology
Working Group additional options such as a nicardipine
infusion, or sodium nitroprusside infusion (with or with-
out β-blockers or angiotensin converting enzyme inhibi-
tors) should be considered in hypertensive urgencies and
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Figure 1 demonstrates that there was a decrease in systolic,
diastolic, and mean blood pressures 1–2 hours before-
hand, and, therefore, the more serious drop in blood pres-
sure may have been preventable. Our report is only the
second case that we can identify in the literature in which
a labetalol infusion has been documented to cause a con-
dition of cardiovascular collapse secondary to β-blocker
toxicity.
Conclusion
The medical literature indicates that labetalol is relatively
safe to use. However, vigilance is required when it is
administered in the form of an intravenous infusion
because of the frequency with which the recommended
intravenous dose may be exceeded with its prolonged use.
We recommend that surgical intensive care units using
labetalol infusions to control refractory hypertension
have glucagon, epinephrine, insulin, phosphodiesterase
inhibitors, and vasopressin readily available for adminis-
tration.
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